SPY375.70-2.76 -0.73%
DIA308.12-1.80 -0.58%
IXIC12,998.50-114.14 -0.87%

Cantor Fitzgerald Assumes Amicus Therapeutics at Overweight, Raises $20 Price Target

Cantor Fitzgerald analyst Eliana Merle assumes Amicus Therapeutics (NASDAQ:FOLD) with a Overweight rating and a $20 price target.

Benzinga · 02/04/2020 11:53

Cantor Fitzgerald analyst Eliana Merle assumes Amicus Therapeutics (NASDAQ:FOLD) with a Overweight rating and a $20 price target.